Cross-Functional Product Launch Excellence in KSA (Pharmaceuticals)

(Pharmaceuticals) Commercializing a new pharmaceutical asset in Saudi Arabia requires error-free synchronization of SFDA approvals, NUPCO pricing negotiations, and procurement alignment across all 21 autonomous regional clusters. Historical data shows that even minor misalignment between medical, regulatory, and commercial divisions causes catastrophic launch delays and irrecoverable revenue erosion. This intensive workshop delivers an operational framework for launch excellence built on disciplined cross-functional synergy. Using Saudi-specific historical launch case studies, participants construct synchronized, multi-disciplinary launch roadmaps using advanced project-management methodologies, learning to integrate the timelines of the new SFDA Economic Evaluation Studies guidelines, the long-lead requirements of generating local real-world evidence, and LCGPA local-content strategies into a single cohesive go-to-market plan. The program emphasizes the orchestration of interdependencies: when EES dossiers must be ready, when RWE generation must begin, how NUPCO pricing windows constrain sequencing, and how cluster-by-cluster formulary access dictates field deployment. Participants practice critical-path mapping, risk and contingency planning, and launch-readiness governance. The outcome is a repeatable, cross-functional launch discipline that converts a fragmented sequence of approvals into a coordinated, revenue-protecting commercialization engine.